These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20379102)

  • 1. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
    Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
    Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
    Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
    Murakami H; Handa H; Abe M; Iida S; Ishii A; Ishikawa T; Ishida T; Oota M; Ozaki S; Kosaka M; Sakai A; Sawamura M; Shimazaki C; Shimizu K; Takagi T; Hata H; Fukuhara T; Fujii H; Miyata A; Wakayama T; Takatsuki K
    Eur J Haematol; 2007 Sep; 79(3):234-9. PubMed ID: 17655699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
    Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
    Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
    Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
    Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
    Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
    Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
    Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
    Agata M; Sameshima Y; Oda T; Kondo T; Ishiyama M; Yasunami T; Kazama H; Okamura T; Yoshinaga K; Shiseki M; Mori N; Yamada O; Sagawa K; Teramura M; Motoji T
    Rinsho Ketsueki; 2010 Mar; 51(3):189-95. PubMed ID: 20379113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
    Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
    Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
    Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
    Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.